23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
18:24 , Mar 9, 2018 |  BC Week In Review  |  Financial News

Atara raises $150M in follow-on

Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $150 million on Feb. 28 through the sale of 4.3 million shares at $35 in a follow-on underwritten by J.P. Morgan, Cowen, Canaccord Genuity and Mizuho. The price is an...
16:18 , Mar 1, 2018 |  BC Extra  |  Financial News

Atara raises another $150M in latest follow-on

Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $150 million through the sale of 4.3 million shares at $35 in a follow-on underwritten by J.P. Morgan, Cowen, Canaccord Genuity and Mizuho. The price is an 18% discount to...
08:22 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

Atara reports expanded access protocol data of tabelecleucel

Atara Biotherapeutics Inc. (NASDAQ:ATRA) reported data from a U.S. expanded access protocol study showing that IV tabelecleucel led to an objective response rate (ORR) of 83% among six patients with Rituxan rituximab-refractory Epstein-Barr virus (EBV)...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
22:23 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Atara begins Phase III testing of tabelecleucel to treat EBV-PTLD

Atara Biotherapeutics Inc. (NASDAQ:ATRA) began two open-label, international Phase III trials of tabelecleucel to treat Rituxan rituximab-refractory Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (EBV-PTLD). The MATCH trial will evaluate tabelecleucel in EBV-PTLD patients who had an...
21:10 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Atara prices $127.8M follow-on

Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $127.8 million on Jan. 3 through the sale of 7 million shares at $18.25 in a bumped-up follow-on underwritten by JPMorgan, Cowen, William Blair and Canaccord Genuity. The price is...
21:28 , Jan 4, 2018 |  BC Extra  |  Financial News

Atara prices $127.8M follow-on

Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $127.8 million through the sale of 7 million shares at $18.25 in a bumped-up follow-on underwritten by JPMorgan, Cowen, William Blair and Canaccord Genuity. The price is a slight premium...
23:19 , Dec 29, 2017 |  BC Extra  |  Clinical News

Atara gains on Phase III plans for cell therapy

Atara Biotherapeutics Inc. (NASDAQ:ATRA) gained $2.85 (19%) to $18.10 Friday after FDA cleared the company to begin two Phase III trials of tabelecleucel (formerly ATA129) to treat Rituxan rituximab-refractory Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease...
23:19 , Oct 20, 2017 |  BC Extra  |  Politics & Policy

EMA publishes ATMP action plan

EMA and EC's Directorate-General for Health and Food Safety (DG SANTE) published a joint action plan intended to foster development of advanced therapy medicinal products (ATMPs), which include therapeutic products made from genes, tissue or...